MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12094-025-04044-3

Медицинская библиотека · Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025

Efficacy and safety of cetuximab-based versus platinum-based chemoradiation in HNSCC: evidence from a meta-analysis of 10 randomized controlled trials.

Kumar Tarun, Kesh Nishu, Pandey Atindra Kumar, Chakrawal Ankita, Singh Bhavana, Pal Manjusha, Rajput Monika, Dixit Ruhi, Pai Esha, Pandey Manoj

СтатьяМетаанализСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Platinum-based chemoradiotherapy (CTRT) is the standard treatment for head and neck squamous cell carcinoma (HNSCC). While cetuximab-based radiotherapy (CxRT) has been proposed as an alternative, its efficacy remains controversial. Multiple meta-analyses have compared CxRT with CTRT for HNSCC though they combined randomized controlled trials (RCTs) with lower-evidence studies, compromising result validity. This study presents the first meta-analysis using exclusively RCT data, providing the highest level of evidence for clinical decision-making.

METHODS

We systematically searched MEDLINE, Embase, Cochrane, and SCOPUS, identifying 10 RCTs (n = 2,557 patients). Primary outcomes included overall survival (OS), disease-free survival (DFS), and all-cause mortality; secondary outcomes were Grade ≥ 3 toxicities. Hazard ratios (HRs) and odds ratios (ORs) were pooled using random effect models.

RESULTS

CxRT was associated with a 50% higher recurrence risk (HR 1.50, 95% CI 1.07-2.10) and 27% increased all-cause mortality (OR 1.27, 95% CI 1.05-1.55) compared to CTRT. OS did not differ significantly (HR 1.33, 95% CI 0.79-2.22). Toxicity profiles varied: CxRT had higher mucositis (OR 1.17, 95% CI 1.04-1.32) and skin rash (OR 3.46, 95% CI 1.28-9.36), while CTRT showed more anemia (OR 0.15, 95% CI 0.05-0.52) and nausea/vomiting (OR 0.31, 95% CI 0.19-0.53).

CONCLUSION

CxRT is inferior to CTRT in HNSCC, with poorer disease control and survival outcomes. The lack of biomarker (EGFR/RAS) stratification in trials may have contributed to suboptimal patient selection. While CxRT may be an option for cisplatin-ineligible patients, platinum-based therapy appears to be the standard. Future research should optimize cetuximab's role through biomarker-driven selection.

Для цитирования: Kumar Tarun, Kesh Nishu, Pandey Atindra Kumar, Chakrawal Ankita, Singh Bhavana, Pal Manjusha, Rajput Monika, Dixit Ruhi, Pai Esha, Pandey Manoj. Efficacy and safety of cetuximab-based versus platinum-based chemoradiation in HNSCC: evidence from a meta-analysis of 10 randomized controlled trials.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2025. DOI: 10.1007/s12094-025-04044-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.